EUDA Health Holdings Limited signed a tri-party Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on the development, manufacturing, and commercialization of next-generation off-the-shelf oncology cell therapies derived from induced pluripotent stem cells. The agreement aims to advance treatments for cancer and wellness applications. EUDA Health Holdings Limited is a Singapore-based distributor of third-party wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia, and China, and also operates a property management business.

EUDA Health Holdings Limited has suspended and subsequently will terminate the At The Market Offering Agreement with Chardan Capital Markets LLC, effective July 22, 2026. The company has suspended the equity offering of up to $10,000,000 in ordinary shares through the commission-based broker-dealerer than Charadan. No ordinary shares have been sold under theing the ATM Offering. EUDA Health Holdings Limited is a healthcare technology company that provides digital health solutions.